Jitterbit Named Leader for 2026 Data Integration Data Quadrant Report by Info-Tech Research Group Bardon Insurance Bolsters Medical Stop-Loss for Self-Funded Employers with Gradient AI
Gradient AI’s Solution Provides Larger Datasets and Deeper Insights to Underwriting Process BOSTON–(BUSINESS WIRE)–#AI—Gradient AI,…
CoreLogic Launches Climate Risk Analytics™ to Model and Predict Property Risk Through 2050
Solution offers a comprehensive view of physical risk, leveraging Google Cloud, that combines hyperlocal property…
Kensu launches first 360 data observability solution to monitor data in motion and at rest in real-time
Observe your data pipelines and data sources in real-time to cut resolution time in half…
Codasip launches SecuRISC5 initiative
New approach to safe and secure custom compute RISC-V Summit, San Jose, 12 December 2022…
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide…
Harvard Bioscience Announces CFO Transition
HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”)…
Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
–FemCerv®, the first endocervical tissue sampler of its kind in the detection of cervical cancer,…
X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia
Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with…
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both
CINCINNATI, Dec. 12, 2022 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water…
UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting
MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood…
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting
Media Release Event to be held live in New Orleans, Louisiana Meeting to be webcast…
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a…
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from…
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor…
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
– $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK,…
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3…
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company…
VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event
BRIDGEWATER, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or…
Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections
Highlights: Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South…